NEI Research News

Three young adults with Leber Congenital Amaurosis-a severe degenerative disease of the retina caused by a mutation in the RPE65 gene-reported improvements in vision after undergoing a specialized gene transfer procedure.

A promising new drug therapy used to treat abnormal swelling in the eye-a condition called diabetic macular edema-proved less effective than traditional laser treatments in a study funded by the National Eye Institute (NEI), part of the NIH.

Two groups of investigators have reported independently on their initial observations from Phase I clinical trials of gene transfer for Leber congenital amaurosis (LCA) caused by mutations in the RPE65 gene.

The age pool of corneas for transplant should be expanded to include donors up to 75 years of age, based on findings from a study funded by the National Eye Institute (NEI), one of the National Institutes of Health.

Most Americans do not know the risks and warning signs of diseases that could blind them if they don’t seek timely detection and treatment.

The National Eye Institute (NEI) of the National Institutes of Health (NIH) announces the start of a multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration

The National Eye Institute (NEI) of the National Institutes of Health (NIH) is supporting a phase I clinical trial to assess the safety of gene transfer in treating people with a form of Leber congenital amaurosis (LCA).

An extensive NIH-supported study has found that low-intensity laser treatment, thought to be possibly beneficial in slowing or preventing the loss of vision from AMD.

Aproximadamente 100 centros clínicos están buscando 4.000 personas entre las edades de 50 a 85 años

Nearly 100 Clinical Centers Are Now Seeking 4,000 Study Participants Ages 50-85 Who Have AMD